What is the current valuation of the biologic therapy market in Italy?

The overall market valuation was $4630.0 Million in 2024. Read More

What is the projected market size for biologic therapy in Italy by 2035?

The projected valuation for 2035 is $6140.0 Million. Read More

What is the expected CAGR for the biologic therapy market in Italy during 2025 - 2035?

The expected CAGR for the market during the forecast period is 2.6%. Read More

Which companies are the key players in the Italy biologic therapy market?

Key players include AbbVie, Amgen, Roche, Johnson & Johnson, Novartis, Bristol-Myers Squibb, Sanofi, Gilead Sciences, and Merck & Co. Read More

How did the Monoclonal Antibodies segment perform in 2024?

The Monoclonal Antibodies segment was valued at $1500.0 Million in 2024. Read More

What is the market size for oncology applications in the biologic therapy sector?

The oncology application segment was valued at $1380.0 Million in 2024. Read More

What routes of administration are prevalent in the Italy biologic therapy market?

The prevalent routes of administration include Intravenous, Subcutaneous, and Intramuscular. Read More

What was the market valuation for home healthcare in the biologic therapy sector in 2024?

The home healthcare segment was valued at $1580.0 Million in 2024. Read More

What is the expected growth trend for the biologic therapy market in Italy?

The market is likely to experience steady growth, reaching $6140.0 Million by 2035. Read More

Italy Biologic Therapy Market

Q: What are the main segments of the biologic therapy market in Italy?

The main segments include Monoclonal Antibodies, Vaccines, Cell Therapy, and Gene Therapy. Read More

ID: MRFR/Pharma/52748-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

Italy Biologic Therapy Market Research Report By Therapy Type (Monoclonal Antibodies, Vaccines, Cell Therapy, Gene Therapy), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By Route of Administration (Intravenous, Subcutaneous, Intramuscular) and By End User (Hospitals, Clinics, Home Healthcare) - Growth & Industry Forecast 2025 To 2035

Italy Biologic Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)2.6%

2024 Market Size$ 4,630 Million

2025 Market Size$ 4,750.38 Million

2035 Market Size$ 6,140 Million

Key Players

AbbVie

Amgen

Roche

Johnson & Johnson

Novartis

Bristol-Myers Squibb

Trends

Rising Investment in Research and Development
Growing Adoption of Personalized Medicine
Enhanced Regulatory Support for Biologics

Opportunities

Advancements in Biotechnology
Rising Healthcare Expenditure
Supportive Healthcare Policies

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 Monoclonal Antibodies
  2. 4.1.2 Vaccines
  3. 4.1.3 Cell Therapy
  4. 4.1.4 Gene Therapy
2. 4.2 Life Sciences, BY Application (USD Million)
  1. 4.2.1 Oncology
  2. 4.2.2 Autoimmune Diseases
  3. 4.2.3 Infectious Diseases
  4. 4.2.4 Cardiovascular Diseases
3. 4.3 Life Sciences, BY Route of Administration (USD Million)
  1. 4.3.1 Intravenous
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Intramuscular
4. 4.4 Life Sciences, BY End-user (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Home Healthcare
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Amgen (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bristol-Myers Squibb (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Gilead Sciences (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Merck & Co. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 ITALY MARKET ANALYSIS BY TYPE
3. 6.3 ITALY MARKET ANALYSIS BY APPLICATION
4. 6.4 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 ITALY MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Italy Biologic Therapy Market Segmentation

Italy Biologic Therapy Market By Type (USD Million, 2025-2035)

Monoclonal Antibodies
Vaccines
Cell Therapy
Gene Therapy

Italy Biologic Therapy Market By Application (USD Million, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases
Cardiovascular Diseases

Italy Biologic Therapy Market By Route of Administration (USD Million, 2025-2035)

Intravenous
Subcutaneous
Intramuscular

Italy Biologic Therapy Market By End-user (USD Million, 2025-2035)

Hospitals
Clinics
Home Italy Biologic Therapy Market

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”